Literature DB >> 17992602

Bone morphogenetic proteins regulate osteoprotegerin and its ligands in human vascular smooth muscle cells.

Kirsten Q T Nguyen1, Ping Olesen, Thomas Ledet, Lars Melholt Rasmussen.   

Abstract

The bone-related protein osteoprotegerin (OPG) may be involved in the development of vascular calcifications, especially in diabetes, where it has been found in increased amounts in the arterial wall. Experimental studies suggest that members of the TGF-superfamily are involved in the transformation of human vascular smooth muscle cells (HVSMC) to osteoblast-like cells. In this study, we evaluated the effect of BMP-2, BMP-7 and transforming growth factor beta (TGF-beta1) on the secretion and mRNA expression of OPG and its ligands receptor activator of nuclear factor-kappabeta ligand (RANKL) and TNF-related apoptosis-inducing ligand (TRAIL) in HVSMC. All three growth factors decreased OPG protein production significantly; these results were paralleled by reduced OPG mRNA expression. TRAIL mRNA levels were also decreased. RANKL mRNA expression declined when treated with TGF-beta1 but were increased by both BMPs. Members of the TGF-superfamily, i.e. TGF-beta1, BMP-2 and BMP-7 exert effects on OPG and its ligands, indicating that these peptides may be involved in the development of vascular calcifications. The downregulation of OPG by these peptides does, however, not suggest that these factors are directly involved in OPG accumulation in diabetes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17992602     DOI: 10.1007/s12020-007-9007-0

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  39 in total

1.  Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus.

Authors:  S Lehto; L Niskanen; M Suhonen; T Rönnemaa; M Laakso
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-08       Impact factor: 8.311

2.  Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D.

Authors:  P A Price; H H June; J R Buckley; M K Williamson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-10       Impact factor: 8.311

3.  Bone formation and inflammation in cardiac valves.

Authors:  E R Mohler; F Gannon; C Reynolds; R Zimmerman; M G Keane; F S Kaplan
Journal:  Circulation       Date:  2001-03-20       Impact factor: 29.690

4.  Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients.

Authors:  Lars Melholt Rasmussen; Lise Tarnow; Troels Krarup Hansen; Hans-Henrik Parving; Allan Flyvbjerg
Journal:  Eur J Endocrinol       Date:  2006-01       Impact factor: 6.664

5.  Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha.

Authors:  P Olesen; T Ledet; L M Rasmussen
Journal:  Diabetologia       Date:  2005-02-08       Impact factor: 10.122

Review 6.  Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator.

Authors:  Fuad N Ziyadeh
Journal:  J Am Soc Nephrol       Date:  2004-01       Impact factor: 10.121

7.  Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice.

Authors:  D A Towler; M Bidder; T Latifi; T Coleman; C F Semenkovich
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

8.  Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines.

Authors:  L C Hofbauer; C R Dunstan; T C Spelsberg; B L Riggs; S Khosla
Journal:  Biochem Biophys Res Commun       Date:  1998-09-29       Impact factor: 3.575

9.  MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors.

Authors:  Su-Li Cheng; Jian-Su Shao; Nichole Charlton-Kachigian; Arleen P Loewy; Dwight A Towler
Journal:  J Biol Chem       Date:  2003-08-18       Impact factor: 5.157

10.  Regulatory role of endothelium in the expression of genes affecting arterial calcification.

Authors:  Clarissa Cola; Maria Almeida; Dayuan Li; Francesco Romeo; Jawahar L Mehta
Journal:  Biochem Biophys Res Commun       Date:  2004-07-23       Impact factor: 3.575

View more
  6 in total

1.  Runx2-upregulated receptor activator of nuclear factor κB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages.

Authors:  Chang Hyun Byon; Yong Sun; Jianfeng Chen; Kaiyu Yuan; Xia Mao; Jack M Heath; Peter G Anderson; Yin Tintut; Linda L Demer; Deli Wang; Yabing Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-03-31       Impact factor: 8.311

Review 2.  Medial arterial calcification in diabetes and its relationship to neuropathy.

Authors:  W J Jeffcoate; L M Rasmussen; L C Hofbauer; F L Game
Journal:  Diabetologia       Date:  2009-09-12       Impact factor: 10.122

3.  RANKL Inhibits the Production of Osteoprotegerin from Smooth Muscle Cells under Basal Conditions and following Exposure to Cyclic Strain.

Authors:  Colin Davenport; Emma Harper; Keith D Rochfort; Hannah Forde; Diarmuid Smith; Philip M Cummins
Journal:  J Vasc Res       Date:  2018-04-10       Impact factor: 1.934

4.  Low bone volume--a risk factor for coronary calcifications in hemodialysis patients.

Authors:  Teresa Adragao; Johann Herberth; Marie-Claude Monier-Faugere; Adam J Branscum; Anibal Ferreira; Joao M Frazao; Jose Dias Curto; Hartmut H Malluche
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-21       Impact factor: 8.237

5.  Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact.

Authors:  Penny E Reid; Nicola J Brown; Ingunn Holen
Journal:  Mol Cancer       Date:  2009-07-15       Impact factor: 27.401

6.  Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension.

Authors:  Abdul G Hameed; Nadine D Arnold; Janet Chamberlain; Josephine A Pickworth; Claudia Paiva; Sarah Dawson; Simon Cross; Lu Long; Lan Zhao; Nicholas W Morrell; David C Crossman; Christopher M H Newman; David G Kiely; Sheila E Francis; Allan Lawrie
Journal:  J Exp Med       Date:  2012-10-15       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.